Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), Finished dosages (FD) and Peptides/ CDMO contribute 14%, 10%, 74% and 2% of revenue from operations, respectively, for Q1FY26.
Its Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) declined by 5% year-on-year to ₹247 crore, while margins narrowed by 160 basis points to 20.4% from 22% last year.The company’s net profit declined by 16% from last year to ₹113 crore.
Net debt for the company stood at ₹948 crore, while net debt-to-EBITDA stood at 0.96x.
“We delivered healthy cash flow from operations of ₹280.6 crore this quarter and made good progress on the Gagillapur remediation program. USFDA audits at our Bonthapally API facility, GPI in Virginia, and Granules Life Sciences at Genome Valley were successfully completed with one minor observation each. The Danish Medicines Agency also concluded its EU GMP inspection of Gagillapur with certification granted,” said Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India.
“With our near-term formulations growth trajectory set to resume, and the integration of Senn Chemicals through the Ascelis platform in the fast-growing CDMO sector, we are well-positioned for sustainable long-term growth,” he added.
Following the earnings announcement, shares of Granules India Ltd. are currently trading 2.17% higher at ₹450.10. The stock has declined 25% so far in 2025.
